# Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

> **NCT05503667** · PHASE2 · RECRUITING · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 96 (estimated)

## Conditions studied

- Lung Adenocarcinoma Stage III
- Lung Adenocarcinoma Stage IV
- EGFR Gene Mutation

## Interventions

- **DRUG:** Furmonertinib
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05503667
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-01
- **Primary completion:** 2023-10-01
- **Final completion:** 2028-12-31
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2022-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05503667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05503667, "Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05503667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*